Jaret Malloy

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Richard M. Bergenstal, Carol Wysham, Leigh MacConell et al. · The Lancet · 2010 · 605 citations

Weekly Versus Sitagliptin, Diabetes Management, Randomised Trial +8

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

Thomas Blevins, John Pullman, Jaret Malloy et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 442 citations · Full text

One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients

Mathijs C. Bunck, Michaëla Diamant, A. H. Corner et al. · Diabetes Care · 2009 · 385 citations · Full text

Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial

Michaëla Diamant, Luc Van Gaal, Bruno Guerci et al. · The Lancet Diabetes & Endocrinology · 2014 · 152 citations

Diabetes Management, Insulin Management, Diabetes +9

<i>Pseudomonas aeruginosa</i>protease IV degrades surfactant proteins and inhibits surfactant host defense and biophysical functions

Jaret Malloy, Ruud A. W. Veldhuizen, Brett A. Thibodeaux et al. · American Journal of Physiology-Lung Cellular and Molecular Physiology · 2004 · 130 citations

Pulmonary Surfactant, Inflammatory Lung Disease, Immunology +17